{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:53:43Z","timestamp":1793912023173,"version":"4.8.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.semradonc.2022.11.008","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T10:23:10Z","timestamp":1679912590000},"page":"181-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Role of Stereotactic Body Radiation Therapy in the Management of Liver Metastases"],"prefix":"10.1016","volume":"33","author":[{"given":"Sangjune Laurence","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad G.","family":"Rusthoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2022.11.008_bib0001","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ijrobp.2020.02.019","article-title":"Oligometastasis: past, present, future","volume":"108","author":"Gutiontov","year":"2020","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0002","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3389\/fonc.2019.00543","article-title":"A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: where will the evidence lead?","volume":"9","author":"Al-Shafa","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0003","doi-asserted-by":"crossref","unstructured":"Kavanagh BD, Kelly K, Kane M. The promise of stereotactic body radiation therapy in a new era of oncology. IMRT IGRT SBRT - Adv Treat Plan Deliv Radiother. 2007;40:340-351. https:\/\/doi.org\/10.1159\/000106045.","DOI":"10.1159\/000106045"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0004","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/hep.13.12","article-title":"Rationale for ablation of oligometastatic disease and the role of stereotactic body radiation therapy for hepatic metastases","volume":"1","author":"Rusthoven","year":"2014","journal-title":"Hepatic Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0005","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","article-title":"Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib","volume":"88","author":"Gan","year":"2014","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0006","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/439752","article-title":"The confluence of stereotactic ablative radiotherapy and tumor immunology","author":"Finkelstein","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0007","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00066-013-0450-y","article-title":"Definition of stereotactic body radiotherapy","volume":"190","author":"Guckenberger","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET) \u2013 extended long-term outcomes","author":"Harrow","year":"2022","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0009","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0010","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0011","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC","author":"Wang","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0013","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0014","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ijrobp.2021.09.014","article-title":"Consolidative use of radiotherapy to block (CURB) oligoprogression \u2015 interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast","volume":"111","author":"Tsai","year":"2021","journal-title":"Int J Radiat Oncol"},{"issue":"16_suppl","key":"10.1016\/j.semradonc.2022.11.008_bib0015","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: a phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.semradonc.2022.11.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.3501","article-title":"Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC)","volume":"33","author":"Ruers","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0017","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semradonc.2018.06.009","article-title":"A contemporary update on the role of stereotactic body radiation therapy (sbrt) for liver metastases in the evolving landscape of oligometastatic disease management","volume":"28","author":"Robin","year":"2018","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0018","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized phase ii trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0019","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00000658-200206000-00002","article-title":"Trends in long-term survival following liver resection for hepatic colorectal metastases","volume":"235","author":"Choti","year":"2002","journal-title":"Ann Surg"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/SLA.0b013e3181bfda3c","article-title":"Correlation between postoperative infective complications and long-term outcomes after hepatic resection for colorectal liver metastasis","volume":"251","author":"Farid","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0021","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jamcollsurg.2009.12.041","article-title":"Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients","volume":"210","author":"Nathan","year":"2010","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0022","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/SLA.0b013e3181b4539b","article-title":"Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients","volume":"250","author":"de Jong","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0023","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00268-007-9348-0","article-title":"Prognostic models for predicting death after hepatectomy in individuals with hepatic metastases from colorectal cancer","volume":"32","author":"Kanemitsu","year":"2008","journal-title":"World J Surg"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0024","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/SLA.0b013e31815aa2c2","article-title":"Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients","volume":"247","author":"Rees","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0025","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/SLA.0b013e318142d964","article-title":"Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases","volume":"246","author":"Malik","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0026","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jamcollsurg.2007.06.283","article-title":"Survival after liver resection for metastatic colorectal carcinoma in a large population","volume":"205","author":"Shah","year":"2007","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0027","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1245\/ASO.2006.05.039","article-title":"Survival after hepatic resection for colorectal metastases: a 10-year experience","volume":"13","author":"Wei","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0028","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/01.sla.0000160703.75808.7d","article-title":"Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases","volume":"241","author":"Pawlik","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0029","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0031","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/codi.15113","article-title":"Pulmonary metastasectomy in colorectal cancer: updated analysis of 93 randomized patients \u2013 control survival is much better than previously assumed","volume":"22","author":"Milosevic","year":"2020","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0032","unstructured":"Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol.:10."},{"key":"10.1016\/j.semradonc.2022.11.008_bib0033","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S1470-2045(13)70101-3","article-title":"Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases","volume":"14","author":"Sahgal","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2020.101760","article-title":"Epidemiology of liver metastases","volume":"67","author":"Horn","year":"2020","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13014-018-1185-9","article-title":"Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5\u2009years of follow-up","volume":"13","author":"Scorsetti","year":"2018","journal-title":"Radiat Oncol Lond Engl"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0036","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13014-018-0969-2","article-title":"Stereotactic body radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional rssearch\u00ae patient registry","volume":"13","author":"Mahadevan","year":"2018","journal-title":"Radiat Oncol Lond Engl"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0037","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.radonc.2018.06.035","article-title":"Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review","volume":"129","author":"Petrelli","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0038","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO.2001.19.1.164","article-title":"Stereotactic single-dose radiation therapy of liver tumors: results of a phase I\/II trial","volume":"19","author":"Herfarth","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0039","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ijrobp.2005.01.002","article-title":"A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases","volume":"62","author":"Schefter","year":"2005","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0040","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/02841860600904854","article-title":"Phase II study on stereotactic body radiotherapy of colorectal metastases","volume":"45","author":"Hoyer","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0041","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/02841860600897934","article-title":"Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study","volume":"45","author":"M\u00e9ndez Romero","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0042","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","article-title":"Phase I study of individualized stereotactic body radiotherapy of liver metastases","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0043","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0044","first-page":"3381","article-title":"Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results","volume":"29","author":"Ambrosino","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0045","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijrobp.2009.08.020","article-title":"Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies","volume":"78","author":"Goodman","year":"2010","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0046","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1245\/s10434-010-1405-5","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases","volume":"18","author":"Rule","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0047","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3109\/0284186X.2013.766362","article-title":"Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases","volume":"52","author":"Stintzing","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0048","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00432-014-1833-x","article-title":"Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer","volume":"141","author":"Scorsetti","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0049","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1245\/s10434-015-4579-z","article-title":"A phase I dose-escalation trial of single-fraction stereotactic radiation therapy for liver metastases","volume":"23","author":"Meyer","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0050","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ijrobp.2017.04.010","article-title":"Long-term outcomes of phase 1 and 2 studies of SBRT for hepatic colorectal metastases","volume":"99","author":"McPartlin","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0051","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.radonc.2018.01.004","article-title":"A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy","volume":"126","author":"Moon","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0052","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12885-018-4191-2","article-title":"The SBRT database initiative of the German society for radiation oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases","volume":"18","author":"Andratschke","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0053","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","article-title":"radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy","volume":"95","author":"Ahmed","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0054","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2021.01.004","article-title":"Phase 3 multi-center, prospective, randomized trial comparing single-dose 24 gy radiation therapy to a 3-fraction SBRT regimen in the treatment of oligometastatic cancer","volume":"110","author":"Zelefsky","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195149","article-title":"Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis","volume":"13","author":"Hong","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0056","first-page":"91","article-title":"Predicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases","volume":"36","author":"Lindberg","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0057","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1748-717X-7-148","article-title":"Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors","volume":"7","author":"Kress","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0058","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13014-017-0818-8","article-title":"Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer","volume":"12","author":"Mutsaers","year":"2017","journal-title":"Radiat Oncol Lond Engl"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0059","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.radonc.2018.09.011","article-title":"Quality of life changes after stereotactic ablative radiotherapy for liver metastases: a prospective cohort analysis","volume":"129","author":"Helou","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11912-017-0599-0","article-title":"Cost-effectiveness of stereotactic radiosurgery and stereotactic body radiation therapy: a critical review","volume":"19","author":"Lester-Coll","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0061","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ijrobp.2016.02.045","article-title":"Cost-effectiveness analysis of stereotactic body radiation therapy compared with radiofrequency ablation for inoperable colorectal liver metastases","volume":"95","author":"Kim","year":"2016","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0062","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.clon.2020.08.010","article-title":"Cost-effectiveness analysis of stereotactic ablative body radiation therapy compared with surgery and radiofrequency ablation in two patient cohorts: metastatic liver cancer and hepatocellular carcinoma","volume":"33","author":"Jin","year":"2021","journal-title":"Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0063","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijrobp.2015.04.016","article-title":"Prospective longitudinal assessment of quality of life for liver cancer patients treated with stereotactic body radiation therapy","volume":"93","author":"Klein","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0064","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10102131","article-title":"Limited Liver or lung colorectal cancer metastases. systemic treatment, surgery, ablation or SBRT","volume":"10","author":"Molla","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.radonc.2019.12.004","article-title":"Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review","volume":"145","author":"Lee","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0066","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12032-020-01377-7","article-title":"Thermal ablation versus SBRT in liver tumours: pros and cons","volume":"37","author":"Loi","year":"2020","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0067","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ijrobp.2017.12.014","article-title":"Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases","volume":"100","author":"Jackson","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0068","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.12.288","article-title":"Local control after stereotactic body radiation therapy for liver tumors","volume":"110","author":"Ohri","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0069","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ijrobp.2020.12.012","article-title":"Long-term results of a phase 1 dose-escalation trial and subsequent institutional experience of single-fraction stereotactic ablative radiation therapy for liver metastases","volume":"109","author":"Folkert","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0070","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clon.2022.02.009","article-title":"How low can you go? The radiobiology of hypofractionation","volume":"34","author":"Brand","year":"2022","journal-title":"Clin Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0071","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.radonc.2013.06.045","article-title":"Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11days: a comparison of acute toxicity and quality of life","volume":"108","author":"Jain","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0072","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.prro.2018.06.005","article-title":"Effect of daily and every other day stereotactic body radiation therapy schedules on treatment-related fatigue in patients with hepatocellular carcinoma","volume":"9","author":"Hasan","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0073","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.soc.2020.08.006","article-title":"External beam radiation therapy for liver metastases","volume":"30","author":"Romesser","year":"2021","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0074","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/j.prro.2020.01.012","article-title":"Dose-escalated radiation therapy for pancreatic cancer: a simultaneous integrated boost approach","volume":"10","author":"Koay","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.adro.2021.100652","article-title":"In silico single-fraction stereotactic ablative radiotherapy for the treatment of thoracic and abdominal oligometastatic disease with online adaptive magnetic resonance guidance","author":"Lee","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0076","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/17474124.2020.1814744","article-title":"Radiation-induced liver disease in the era of SBRT: a review","volume":"14","author":"De","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0077","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijrobp.2017.12.290","article-title":"Radiation dose-volume effects for liver SBRT","volume":"110","author":"Miften","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0078","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ijrobp.2017.01.221","article-title":"Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma","volume":"97","author":"Velec","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0079","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0080","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM task group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0081","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0082","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","article-title":"UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy","volume":"34","author":"Diez","year":"2022","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0083","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/j.prro.2021.03.005","article-title":"Organ at risk dose constraints in SABR: a systematic review of active clinical trials","volume":"11","author":"Gerhard","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0084","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.radonc.2016.10.024","article-title":"Central liver toxicity after SBRT: an expanded analysis and predictive nomogram","volume":"122","author":"Toesca","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0085","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/j.prro.2017.02.001","article-title":"Gallbladder toxicity and high-dose ablative-intent radiation for liver tumors: Should we constrain the dose?","volume":"7","author":"Tanguturi","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0086","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.ijrobp.2007.11.042","article-title":"Comparison of different strategies to use four-dimensional computed tomography in treatment planning for lung cancer patients","volume":"70","author":"Wolthaus","year":"2008","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0087","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13014-019-1300-6","article-title":"Clinical impact of removing respiratory motion during liver SABR","volume":"14","author":"Gargett","year":"2019","journal-title":"Radiat Oncol Lond Engl"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0088","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.radonc.2021.11.022","article-title":"A systematic review and meta-analysis of liver tumor position variability during SBRT using various motion management and IGRT strategies","volume":"166","author":"Sharma","year":"2022","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0089","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/acm2.12220","article-title":"Intra- and inter-fractional liver and lung tumor motions treated with SBRT under active breathing control","volume":"19","author":"Lu","year":"2018","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.radonc.2020.04.006","article-title":"4D CT image artifacts affect local control in SBRT of lung and liver metastases","volume":"148","author":"Sentker","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0091","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejmp.2017.07.025","article-title":"The influence of plan modulation on the interplay effect in VMAT liver SBRT treatments","volume":"40","author":"Hubley","year":"2017","journal-title":"Phys Med"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0092","article-title":"The radiobiological impact of motion tracking of liver, pancreas and kidney SBRT tumors in a MR-linac","volume":"63","author":"Al-Ward","year":"2018","journal-title":"Phys Med Ampmathsemicolon Biol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0093","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.radonc.2019.01.023","article-title":"In-vivo treatment accuracy analysis of active motion-compensated liver SBRT through registration of plan dose to post-therapeutic MRI-morphologic alterations","volume":"134","author":"Boda-Heggemann","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0094","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.21037\/jgo-20-424","article-title":"Proton stereotactic body radiation therapy for liver metastases-results of 5-year experience for 81 hepatic lesions","volume":"12","author":"Coffman","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0095","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx031","article-title":"Phase II study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumor genotype","volume":"109","author":"Hong","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0096","doi-asserted-by":"crossref","first-page":"112","DOI":"10.21037\/jgo.2018.08.17","article-title":"A phase I trial of proton stereotactic body radiation therapy for liver metastases","volume":"10","author":"Kang","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0097","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41598-020-58108-1","article-title":"Palliative liver radiotherapy (RT) for symptomatic hepatocellular carcinoma (HCC)","volume":"10","author":"Yeung","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0098","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.2147\/OTT.S165878","article-title":"Stereotactic body radiotherapy using the CyberKnife® system in the treatment of patients with liver metastases: state of the art","volume":"11","author":"Ihn\u00e1t","year":"2018","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0099","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jviscsurg.2014.01.003","article-title":"Treatment of hepatic metastases of colorectal cancer by robotic stereotactic radiation (Cyberknife\u00ae)","volume":"151","author":"Peiffert","year":"2014","journal-title":"J Visc Surg"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.radonc.2021.06.005","article-title":"Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: A prospective phase I trial","volume":"170","author":"van Dams","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0101","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2018.05.048","article-title":"MR-guided gated stereotactic radiation therapy delivery for lung, adrenal, and pancreatic tumors: a geometric analysis","volume":"102","author":"van Sornsen de Koste","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0102","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.radonc.2015.10.024","article-title":"Gadoxetate for direct tumor therapy and tracking with real-time MRI-guided stereotactic body radiation therapy of the liver","volume":"118","author":"Wojcieszynski","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0103","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.radonc.2022.01.009","article-title":"Technical feasibility and clinical evaluation of 4D-MRI guided liver SBRT on the MR-linac","volume":"167","author":"van de Lindt","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0104","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3390\/cancers14030716","article-title":"MRI-guided online adaptive stereotactic body radiation therapy of liver and pancreas tumors on an MR-linac system","volume":"14","author":"Stanescu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0105","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijrobp.2018.09.011","article-title":"Tumor trailing for liver SBRT on the MR-linac","volume":"103","author":"Fast","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0106","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13014-022-02033-2","article-title":"MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial","volume":"17","author":"Hoegen","year":"2022","journal-title":"Radiat Oncol Lond Engl"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0107","article-title":"Initial clinical experience of stereotactic body radiation therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 Tesla MR-Linac","volume":"15","author":"Hall","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0108","article-title":"MR-guided radiotherapy for liver malignancies","volume":"0","author":"Boldrini","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.semradonc.2022.11.008_bib0109","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/S1470-2045(20)30034-6","article-title":"MRI-guided adaptive radiotherapy for liver tumours: visualising the future","volume":"21","author":"Witt","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429622000807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429622000807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:53:49Z","timestamp":1760950429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429622000807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1053429622000807"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2022.11.008","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Stereotactic Body Radiation Therapy in the Management of Liver Metastases","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2022.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}